New hope for myeloma patients with kidney failure: drug combo shows promise

NCT ID NCT06142396

First seen Mar 21, 2026 · Last updated May 12, 2026 · Updated 6 times

Summary

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failure. The goal is to see how well the treatment shrinks the cancer and improves kidney function. About 30 participants will be enrolled, and the study will also compare results between African American and non-African American patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Georgia Cancer Center-Augusta University

    RECRUITING

    Augusta, Georgia, 30912, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.